ARS Pharmaceuticals, Inc. Common Stock
SPRYARS Pharmaceuticals, Inc. (SPRY) is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of acute care medical conditions. The company primarily specializes in rescue treatments for severe allergies, anaphylaxis, and other urgent medical needs, aiming to improve patient outcomes through its proprietary drug delivery systems.
Company News
ARS Pharmaceuticals reported $32.5 million in revenue for Q3 2025, primarily from neffy epinephrine nasal spray sales. The company continues to expand market presence through direct-to-consumer campaigns and has strong cash reserves of $288.2 million.
ARS Pharmaceuticals reported strong Q2 2025 revenue of $15.7 million, driven by its needle-free epinephrine nasal spray neffy. Prescription volumes grew 180%, and commercial coverage reached 93%, though high operating costs led to a net loss of $44.9 million.
ARS Pharmaceuticals has filed for approval of its epinephrine nasal spray 'neffy' in Canada and the United Kingdom, where it will be marketed as 'EURneffy', on behalf of its licensing partner ALK-Abelló A/S. The filing is part of the company's efforts to expand the global availability of this life-saving treatment for severe allergic reactions.
ARS Pharmaceuticals announced that its licensing partners in China, Japan, and Australia have filed for regulatory approval of its epinephrine nasal spray, neffy, for the treatment of type I allergic reactions including anaphylaxis. The company is focused on making this life-saving treatment widely available globally.
ARS Pharmaceuticals, a biopharmaceutical company, announced that its authorized partners in China, Japan, and Australia have submitted applications for the approval of the 2 mg dose of neffy, its epinephrine nasal spray, in their respective countries. The 2 mg dose of neffy was recently approved in the US for the treatment of type I allergic reac...
